The Ebola outbreak in West Africa has reached epidemic levels affecting multiple countries. Over 15,000 people have contracted Ebola and nearly 6,000 have died. Experimental treatments and vaccinations are underway but these efforts are in their early discovery. Increased global travel and an incubation period of up to three weeks makes getting Ebola transmission under control difficult.
Thermo Fisher Scientifics' Mission to enable a healthier, cleaner and safer world feeds very well into the collaborative nature of combating this dangerous disease. This webinar will focus upon technologies and collaborative efforts involved in prevention, diagnosis and treatment.
Dan Didier
Head of Public Health
Thermo Fisher Scientific
Howard Young, Ph.D.
Deputy Chief
NCI Laboratory of Experimental Immunology
Dr. Dan Didier brings more than 30 years of experience to his role as Head of Public Health at Thermo Fisher Scientific. He works closely with the US-CDC, PHE, WHO and their affiliates around the world. He provides Congressional briefings and White house debriefings.
Before joining Applied Biosystems which later became Life Technologies and subsequently Thermo Fisher Scientific, Dan was a serial entrepreneur. Dan was founder, President and CEO of Cytogenomics, SilicoCyte, NuGene, DNA Tree, ScriptAlert and Healthy Biome. Prior to starting these companies he was President of Incyte Genomics Asia and a research head at Monsanto.
Dr. Howard Young received his PhD from the Department of Microbiology and Immunology at the University of Washington and did postdoctoral research under Drs. Edward Scolnick and Wade Parks at the National Cancer Institute. He joined the National Cancer Institute in 1983 and became Deputy Chief of the NCI Laboratory of Experimental Immunology in 2006.
His research has focused on the analysis of cytokine gene expression and signaling with a special emphasis on the molecular characterization of the transcriptional and post transcriptional regulation of Interferon-g in NK cells.
Most recently, his laboratory has developed novel mouse models of lupus and aplastic anemia based on chronic expression of low levels of this important immunoregulatory molecule in the murine C57BL/6 genetic background and the Balb/c genetic background, respectively. He is also collaborating with a laboratory in Malaysia on the development of probiotic microorganisms as carriers for vaccine delivery systems.
Dr. Young is a former President of the International Society for Interferon and Cytokine Research and is a co-recipient (with Dr. Sidney Pestka) of the first Distinguished Service Award from the ISICR, is a two time recipient of the National Cancer Institute Director’s Award for Mentoring and is a recipient of the National Public Service Award from the American Society for Public Administration and the National Academy of Public Administration.
He has also served as Chair of the Immunology Division of the American Society for Microbiology, Chair of the NIH Immunology Interest Group and Cytokine Interest Group and is a member of the American Academy of Microbiology.
